Consequently, our observations would imply that therapeutic strategies that help restrain NFkB activation as seen during circumstances of energy excess, such as obesity and age-onset Type II diabetes, may help counter disturbances in mitochondrial homeostasis and impart beneficial effects upon skeletal muscle insulin sensitivity. The gene discussed is NFKB1; the disease is obesity due to melanocortin 4 receptor deficiency.